ACAD
ACADIA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$27.29
−0.58%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- $0.21
- Revenue estimate
- $332.3M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- $0.18
- EPS estimate
- $0.07
- Revenue actual
- $308.0M
- Revenue estimate
- $296.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +358.3%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $35
- PT range
- $25 – $49
- Analysts
- 12
9 Buy3 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | $0.07 | $0.18 | Beat 164.12% | $308.0M |
| May 6, 2026 | $0.04 | $0.02 | Miss -50.00% | $268.1M |
| Feb 25, 2026 | $0.12 | $1.60 | Beat 1233.33% | $284.0M |
| Nov 5, 2025 | $0.14 | $0.26 | Beat 85.71% | $278.6M |
| Aug 6, 2025 | $0.14 | $0.16 | Beat 14.29% | $264.6M |
| May 7, 2025 | $0.10 | $0.11 | Beat 10.00% | $244.3M |
| Feb 26, 2025 | $0.13 | $0.17 | Beat 30.77% | $259.6M |
| Feb 27, 2024 | $0.30 | $0.28 | Miss -6.67% | $231.0M |
| Nov 2, 2023 | -$0.43 | -$0.40 | Beat 6.98% | $211.7M |
| Aug 2, 2023 | -$0.12 | $0.01 | Beat 108.33% | $165.2M |
| Feb 27, 2023 | -$0.25 | -$0.26 | Miss -4.00% | $136.5M |
| Nov 2, 2022 | -$0.18 | -$0.17 | Beat 5.56% | $130.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026